ArticleJournal of neural transmission (Vienna, Austria : 1996)2014
Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol-O-methyltransferase inhibition.
Article in Journal of neural transmission (Vienna, Austria : 1996), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 23 citations in OpenAlex.
- Opicapone as adjunct to levodopa in treated Parkinson's disease without motor complications: A randomized clinical trial.European journal of neurology · 2025Trial
- Discovery and optimization of a novel non-nitrocatechol COMT inhibitor for modulating levodopa metabolism.Journal of pharmaceutical analysis · 2026Article
- Therapeutic drug monitoring in Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2024Review
- Non-oral continuous drug delivery based therapies and sleep dysfunction in Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2023Review
- Role of dopamine agonists in Parkinson's disease therapy.Journal of neural transmission (Vienna, Austria : 1996) · 2023Review
- Experimental Dopamine Reuptake Inhibitors in Parkinson's Disease: A Review of the Evidence.Journal of experimental pharmacology · 2021Review
- Monoamine oxidase-B inhibitors in the treatment of Parkinson's disease: clinical-pharmacological aspects.Journal of neural transmission (Vienna, Austria : 1996) · 2018Review
- Human COMT over-expression confers a heightened susceptibility to dyskinesia in mice.Neurobiology of disease · 2017Article
- Emerging approaches in Parkinson's disease - adjunctive role of safinamide.Therapeutics and clinical risk management · 2016Review
- Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat.British journal of pharmacology · 2015Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Catechol-O-methyltransferase inhibitor addition to levodopa/carbidopa formulations improves motor symptoms and reduces levodopa fluctuations in patients with Parkinson's disease. Objectives were to investigate the effects of entacapone and tolcapone on plasma behaviour of levodopa, its metabolite 3-O-methyldopa and on motor impairment. 22 patients orally received levodopa/carbidopa first, then levodopa/carbidopa/entacapone and finally levodopa/carbidopa plus tolcapone within a 4.5 h interval twice. Maximum concentration, time to maximum level and bioavailability of levodopa did not differ between all conditions each with 200 mg levodopa application as a whole. Catechol-O-methyltransferase inhibition caused less fluctuations and higher baseline levels of levodopa after the first intake and less 3-O-methyldopa appearance. The maximum levodopa concentrations were higher after the second levodopa intake, particularly with catechol-O-methyltransferase inhibition. The motor response to levodopa was better with catechol-O-methyltransferase inhibition than without, tolcapone was superior to entacapone. More continuous levodopa brain delivery and lower 3-O-methyldopa bioavailability caused a better motor response during catechol-O-methyltransferase inhibition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.